Q1 FY2027 Quarterly Activities Update

• Record quarterly revenue of $26.7m, up 23% from Q4 FY26
• Positive operating cash flow of $2.0m
• FY27 revenue guidance reaffirmed at $105m to $115m
• Inventory of $17.5m to support growth
• Expansion into international markets continues

BLS Pharmaceuticals Ltd announced its Q1 FY27 results, highlighting a record quarterly revenue of $26.7m, up 23% from Q4 FY26 and 91% from Q1 FY26. The company also reported a positive operating cash flow of $2.0m and reaffirmed its FY27 revenue guidance at $105m to $115m. Key drivers of the revenue growth included higher manufacturing volumes, growth in white-label and contract manufacturing, and ongoing supply to ADREXpharma in Germany. BLS also invested $2.4m in its Scotland facility and $0.3m in Australian facilities for future growth. The company maintained an inventory of $17.5m to support domestic and international supply commitments.

FY27 revenue guidance reaffirmed at $105m to $115m, adjusted EBITDA margin 23% to 26%

BLS Pharmaceuticals expects continued growth through increased utilisation of manufacturing capacity, international supply agreements, and expanding pharmaceutical manufacturing customer base.